These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 38247816)

  • 1. The Role of Progranulin (PGRN) in the Pathogenesis of Glioblastoma Multiforme.
    Poniatowski ŁA; Woźnica M; Wojdasiewicz P; Mela-Kalicka A; Romanowska-Próchnicka K; Purrahman D; Żurek G; Krawczyk M; Nameh Goshay Fard N; Furtak-Niczyporuk M; Jaroszyński J; Mahmoudian-Sani MR; Joniec-Maciejak I
    Cells; 2024 Jan; 13(2):. PubMed ID: 38247816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness.
    Bandey I; Chiou SH; Huang AP; Tsai JC; Tu PH
    Oncogene; 2015 Apr; 34(14):1853-64. PubMed ID: 24793792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progranulin overexpression predicts overall survival in patients with glioblastoma.
    Wang M; Li G; Yin J; Lin T; Zhang J
    Med Oncol; 2012 Dec; 29(4):2423-31. PubMed ID: 22161130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of progranulin (PGRN) in the pathogenesis and prognosis of breast cancer.
    Purrahman D; Mahmoudian-Sani MR; Saki N; Wojdasiewicz P; Kurkowska-Jastrzębska I; Poniatowski ŁA
    Cytokine; 2022 Mar; 151():155803. PubMed ID: 35066450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum and urine levels of progranulin (PGRN) as a predictor of microglia activation in the early phase of traumatic brain injury: a further link with the development of neurodegenerative diseases.
    Olczak M; Poniatowski ŁA; Siwińska A; Kwiatkowska M; Chutorański D; Wierzba-Bobrowicz T
    Folia Neuropathol; 2021; 59(1):81-90. PubMed ID: 33969679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progranulin as a therapeutic target for dementia.
    Galimberti D; Fenoglio C; Scarpini E
    Expert Opin Ther Targets; 2018 Jul; 22(7):579-585. PubMed ID: 29889573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
    Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
    Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.
    Aldoghachi AF; Aldoghachi AF; Breyne K; Ling KH; Cheah PS
    Neuroscience; 2022 May; 491():240-270. PubMed ID: 35395355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
    Han J; Puri RK
    J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-progranulin/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration.
    Guha R; Yue B; Dong J; Banerjee A; Serrero G
    Breast Cancer Res Treat; 2021 Apr; 186(3):637-653. PubMed ID: 33616772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4-Akt-ERK signalling by inhibiting EGR1-dependent transcription.
    Chen L; Liu YC; Zheng YY; Xu J; Zhang Y; Liu WL; Li ZY; Huang GD; Li WP
    Phytother Res; 2019 Jun; 33(6):1736-1747. PubMed ID: 31006910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ProNGF Expression and Targeting in Glioblastoma Multiforme.
    Marsland M; Dowdell A; Faulkner S; Jobling P; Rush RA; Gedye C; Lynam J; Griffin CP; Baker M; Marsland J; Jiang CC; Hondermarck H
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma.
    Rajesh Y; Biswas A; Kumar U; Banerjee I; Das S; Maji S; Das SK; Emdad L; Cavenee WK; Mandal M; Fisher PB
    Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12324-12331. PubMed ID: 32409605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma.
    Zhao C; Gao Y; Guo R; Li H; Yang B
    Invest New Drugs; 2020 Oct; 38(5):1227-1235. PubMed ID: 31823158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced Bioinformatics Analysis and Genetic Technologies for Targeting Autophagy in Glioblastoma Multiforme.
    Manea AJ; Ray SK
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
    Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
    Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.
    Mekala JR; Adusumilli K; Chamarthy S; Angirekula HSR
    Metab Brain Dis; 2023 Aug; 38(6):1801-1829. PubMed ID: 37249862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progranulin: A conductor of receptors orchestra, a chaperone of lysosomal enzymes and a therapeutic target for multiple diseases.
    Cui Y; Hettinghouse A; Liu CJ
    Cytokine Growth Factor Rev; 2019 Feb; 45():53-64. PubMed ID: 30733059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
    Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
    Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt/β-catenin Antagonists: Exploring New Avenues to Trigger Old Drugs in Alleviating Glioblastoma Multiforme.
    Precilla DS; Kuduvalli SS; Purushothaman M; Marimuthu P; Muralidharan AR; Anitha TS
    Curr Mol Pharmacol; 2022; 15(2):338-360. PubMed ID: 33881978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.